An investigational oral targeted therapy, zipalertinib (CLN-081), demonstrated meaningful tumor responses and a manageable ...

The healthcare provisions include Medicaid work requirements and a broadening of the exemption to Medicare drug price negotiation ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

In an opinion article, investigators argue that gene therapies may not achieve their full potential if the innate inflammation in Duchenne muscular dystrophy is not effectively managed.

In a conversation with Managed Healthcare Executive, Michael Abrams, M.A., managing partner at Numerof & Associates, painted ...

After a one-year follow-up, 10 of 12 patients given the islet cell therapy zimislecel no longer required insulin. Vertex ...

While the impact of Medicaid changes on employer-sponsored insurance remains to be seen, competition between providers is a ...

Climate change and air pollution are growing threats to public health, and new research suggests they may also worsen atopic ...

Absent a federal committee’s recommendation, Duchenne muscular dystrophy advocates are trying to get states to adopt ...

Care gaps in women’s health are closing, thanks to increased cultural awareness of gendered healthcare disparities, according ...

According to Regeneron, the drug is a bispecific antibody that binds to B-cell maturation antigen (BCMA) on cancerous plasma cells and CD3 on T cells, directing the immune system to attack and destroy ...

FDA officials have determined that information regarding the risks for six CAR T-cell therapies can be communicated through product labeling, which includes a boxed warning for the risks of cytokine ...